Y-27632 Dihydrochloride: Selective ROCK Inhibitor for Advanced Cytoskeletal and Tumor Research

Executive Summary: Y-27632 dihydrochloride (SKU: A3008, APExBIO) is a selective, small-molecule inhibitor of Rho-associated protein kinases ROCK1 and ROCK2, with IC₅₀ ≈ 140 nM for ROCK1 and Ki = 300 nM for ROCK2, showing >200-fold selectivity over other kinases (APExBIO data). It disrupts Rho-mediated stress fiber formation and modulates cell cycle progression from G1 to S phase in cell culture models (Luo et al., 2025). The compound is widely used in studies of tumor invasion, stem cell viability, and cytokinesis inhibition, and has demonstrated efficacy in metastasis suppression in animal models. Y-27632 is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water, with recommended storage below -20°C to maintain stability (APExBIO product documentation).

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases that regulate cytoskeletal dynamics, cell contraction, and actin stress fiber formation in eukaryotic cells. The Rho/ROCK pathway is critical for cytokinesis, cell migration, and cell cycle progression (G1 to S phase). Dysregulation of ROCK signaling has been implicated in tumor invasion, metastasis, and stem cell function (Luo et al., 2025). Selective ROCK inhibition enables precise dissection of these processes in vitro and in vivo. Y-27632 dihydrochloride provides researchers with a robust tool to interrogate Rho-mediated cytoskeletal changes in various biological systems, including prostatic smooth muscle, cancer, and stem cell models.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride competitively inhibits ATP binding to the catalytic domains of ROCK1 and ROCK2. This inhibition blocks ROCK-mediated phosphorylation of downstream targets, such as myosin light chain (MLC) and LIM kinase, resulting in reduced actin filament assembly and diminished cellular contractility. The high selectivity (>200-fold over PKC, MLCK, PAK, cAMP-PK) minimizes off-target effects (APExBIO). Inhibition of ROCK disrupts Rho-dependent formation of stress fibers and focal adhesions, impeding cell motility and invasion. Y-27632 also interferes with cytokinesis and cell cycle transitions, particularly the G1 to S phase checkpoint, by modulating cytoskeletal rearrangement.

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 with IC₅₀ ≈ 140 nM and ROCK2 with Ki = 300 nM in kinase activity assays under physiological conditions (APExBIO, product page).
• Exhibits >200-fold selectivity versus PKC, MLCK, PAK, and cAMP-dependent protein kinase in competitive binding assays (APExBIO).
• Suppresses Rho-mediated stress fiber formation and focal adhesion assembly in human and rat prostatic smooth muscle cells (Luo et al., 2025, DOI).
• Reduces tumor invasion and metastasis in pre-carcinoma in vivo models by inhibiting ROCK2, as shown by decreased collagen deposition and downregulation of αSMA, Vimentin, and Fibronectin expression (Luo et al., 2025, DOI).
• Enhances stem cell viability and expansion in organoid and 3D spheroid co-culture models, improving cell survival rates and maintaining pluripotency markers (Luo et al., 2025, DOI).
• Solubility benchmarks: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water at room temperature (APExBIO, product page).
• Recommended storage: solid form at ≤4°C desiccated; stock solutions below -20°C, avoid long-term solution storage (APExBIO).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely utilized for:

• Cell proliferation assays and modulation of G1/S phase transition
• Disrupting Rho-mediated stress fiber formation in cytoskeletal research
• Enhancing viability and expansion of human and animal stem cells in culture
• Suppressing tumor invasion and metastasis in preclinical cancer models
• Investigating cytokinesis inhibition and cell motility
• In vivo administration via intraperitoneal injection in mouse models

Compared to this review on extracellular vesicle modulation, our article extends the focus to specific solubility, selectivity, and cell cycle applications. For advanced cancer workflow insights, see this piece on tumor invasion and EV communication, which we update by including benchmarks for stem cell viability and in vivo use. For protocol troubleshooting and epithelial barrier function, this guide is complementary; our review adds quantitative storage and selectivity data for Y-27632 dihydrochloride.

Common Pitfalls or Misconceptions

• Y-27632 is not effective against non-ROCK kinases at standard working concentrations (≤10 μM); off-target effects are minimal but possible at much higher doses.
• Long-term storage of Y-27632 solutions at room temperature leads to degradation; always store stock solutions at ≤-20°C.
• Not suitable for direct clinical application; for research use only.
• Does not reverse established fibrosis or cancer metastasis; best used in early/pre-carcinoma models.
• May not maintain stem cell pluripotency in the absence of other essential growth factors.

Workflow Integration & Parameters

Y-27632 dihydrochloride (A3008 by APExBIO) is supplied as a solid. Prepare stock solutions in DMSO (≥111.2 mg/mL), ethanol (≥17.57 mg/mL), or water (≥52.9 mg/mL) at room temperature. Store solid at ≤4°C, desiccated. For cell culture, dilute to 1–20 μM in culture medium. In vivo, administer via intraperitoneal injection, adjusting dosing based on mouse weight and experimental protocol. Avoid repeated freeze-thaw cycles for solutions. Integrate into cell proliferation, cytoskeletal, and invasion assays, and combine with organoid or PBMC co-culture systems to study Rho/ROCK signaling. For optimal results, verify batch-specific activity and solubility under your specific buffer and temperature conditions.

Conclusion & Outlook

Y-27632 dihydrochloride remains the gold standard for selective ROCK1/2 inhibition in cell biology, cancer, and stem cell studies. Its established selectivity profile, robust solubility, and well-documented efficacy make it a critical reagent for dissecting Rho/ROCK signaling. Emerging applications include organoid model development and immune-related adverse event (irAE) research. As with all research-use reagents, adherence to optimal storage and handling protocols ensures reproducible results and minimizes experimental artifacts.

For further details on product specifications and ordering, see the Y-27632 dihydrochloride product page at APExBIO.